Cancer Research

The rapid evolution of therapeutic interventions in the oncology sector has necessitated a fundamental shift in how clinical success is quantified, moving beyond immediate tumor shrinkage toward a comprehensive evaluation of patient outcomes over several years. Historically, the primary metrics for

Ivan Kairatov joins us to discuss the shifting landscape of hematologic oncology, bringing his deep expertise in biopharmaceutical innovation to the forefront of the conversation. As a researcher who has spent years navigating the complex pathways of drug development, Kairatov offers a unique

The traditional methodology of identifying genetic mutations in cancer patients often relies on time-consuming processes that destroy precious biopsy samples before a treatment plan can even begin. This fundamental conflict between diagnostic necessity and sample preservation has led to the

The implementation of digital health tools often risks widening the divide between privileged and underserved patient populations, yet recent clinical evidence suggests that standardized remote monitoring may actually be the key to closing these long-standing disparities. The PRO-TECT (AFT-39)

The staggering reality that nearly ninety percent of pharmaceutical candidates fail during clinical trials has forced a fundamental reckoning within the global research community. For many decades, the industry relied almost exclusively on animal models to predict the efficacy and safety of new

Ivan Kairatov is a distinguished figure in the biopharmaceutical industry, possessing a wealth of expertise in research, development, and the integration of innovative technologies into clinical practice. With a career dedicated to understanding the complexities of drug development and the nuances